Skip to main content

Table 2 Ongoing clinical trials evaluating potential therapies in lung carcinoids

From: Systemic treatment for lung carcinoids: from bench to bedside

Molecular target Study identifier Study title Study design Population Intervention Primary endpoint
Angiogenesis NCT01841736 Phase 2 RANDOMIZEDDOUBLE-blind Advanced well differentiated NENs Pazopanib vs PCB PFS
NCT00605566 Phase 2
Single arm
Open-label
Advanced well differentiated NENs Sorafenib + metronomic cyclophosphamide ORR
NCT02795858 Phase 2
Single arm
Open-label
Advanced extra-pancreatic well differentiated NENs Ramucirumab + SSA PFS
NCT01782443 Phase 2
Single arm
Open-label
Advanced well differentiated NENs Ziv-aflibercept PFS
NCT03375320 CABINET Phase 3
Randomized double-blind
Advanced well differentiated NENs Cabozantinib vs PCB PFS
NCT02588170 Phase 3
Randomized double-blind
Advanced extra-pancreatic well differentiated NENs Surufatinib vs PCB PFS
NCT02259725 Phase 2
Single arm
Open-label
Advanced well differentiated NENs Regorafenib PFS
NCT01744249 Phase 2–3
Randomized double-blind
Advanced extra-pancreatic well differentiated NENs Axitinib + Octreotide LAR vs PCB + Octreotide LAR PFS
NCT02399215 Phase 2
Single arm
Open-label
Advanced extra-pancreatic well differentiated NENs Nintedanib PFS
ErbB NCT00843531 Phase 2 Moderately to well differentiated advanced NENs Everolimus + Erlotinib ORR
ALK NCT02568267 STARTRK-2 Phase 2
Basket study
Solid tumors (including NENs) harboring NTRK 1/2/3, ROS1 or ALK rearrangement Entrectinib ORR
CDK 4/6 NCT02420691 Phase 2
Single arm
Open-label
Foregut advanced well differentiated NENs Ribociclib ORR
NCT03070301 Phase 2
Single arm
Open-label
Foregut advanced well differentiated NENs Ribociclib + Everolimus PFS
Immuno-therapy NCT02955069 Phase 2
Single arm
Open-label
Advanced well differentiated NENs of pancreatic, GI or thoracic origin and advanced GEP-NECs PDR-001 ORR
NCT03278379 NET-002 Phase 2
Single arm
Open-label
Advanced well differentiated
NENs
Avelumab ORR
NCT03420521 Phase 2
Single arm
Open-label
Advanced well differentiated NENs of pancreatic, GI or lung origin (3 cohorts) Nivolumab + Ipilimumab ORR
NCT02923934 Phase 2
Single arm
Open-label
Rare cancers (including NENs) Nivolumab + Ipilimumab CBR
NCT03095274 DUNE Phase 2
Single arm
Open-label
Advanced well differentiated NENs of pancreatic, GI or lung origin and advanced GEP-NECs (4 cohorts) Durvalumab + Tremelimumab CBR
NCT03728361 Phase 2
Single arm
Open-label
Progressive SCLC and advanced NENs (2 cohorts) Nivolumab + Temozolomide ORR
  1. PCB placebo, PFS progression free survival, ORR objective response rate, SSAs somatostatin analogs, ORR objective response rate, GI gastrointestinal, GEP-NECs gastroenteropancreatic neuroendocrine carcinomas, CBR clinical benefit rate, SCLC small cell lung cancer